title: Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.).
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Carnicelli
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.).
authors.forename: Raffaele
authors.initials: R
authors.lastname: De Caterina
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.).
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Halperin
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.).
authors.forename: Giulia
authors.initials: G
authors.lastname: Renda
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.).
authors.forename: Christian T
authors.initials: CT
authors.lastname: Ruff
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.).
authors.forename: Marco
authors.initials: M
authors.lastname: Trevisan
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.).
authors.forename: Francesco
authors.initials: F
authors.lastname: Nordio
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.).
authors.forename: Michele F
authors.initials: MF
authors.lastname: Mercuri
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.).
authors.forename: Elliott
authors.initials: E
authors.lastname: Antman
authors.affiliation: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA (A.P.C.); Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (R.D.C., G.R.); Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (J.L.H.); TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA (C.T.R., M.T., F.N., E.A., R.P.G.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.P.M.). rgiugliano@partners.org.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Giugliano
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D001705:Bioprosthesis / Q000009:adverse effects; D001777:Blood Coagulation / Q000187:drug effects; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects; D013923:Thromboembolism / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D011725:Pyridines; D013844:Thiazoles; D014859:Warfarin; C552171:edoxaban
keywords: anticoagulation; atrial fibrillation; bioprosthetic valve; edoxaban; warfarin